CV Therapeutics Ranexa review
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee will review CV Therapeutics Ranexa (ranolazine) for treatment of chronic stable angina at its Dec. 9 meeting. Review of the partial fatty acid oxidation inhibitor was previously scheduled for mid-September but was cancelled because FDA and the company did not have enough time to prepare for the meeting. The meeting will take place at the Hilton in Gaithersburg, Md. beginning at 8 a.m. [To 1watch a webcast of the meeting, go to FDAAdvisoryCommittee.com]...